Published in Open J Hematol on February 21, 2012
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia (2014) 0.88
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol (2014) 0.87
Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget (2016) 0.75
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cell Oncol (Dordr) (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Rho GTPases in cell biology. Nature (2002) 22.81
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med (2004) 11.71
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 11.41
Multiple myeloma. N Engl J Med (2004) 10.81
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) J Exp Med (1996) 7.97
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Multiple myeloma. Blood (2008) 5.88
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol (1996) 5.41
Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J (1996) 5.14
Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol (2001) 4.99
Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol (2004) 4.22
Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol (2003) 4.16
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 4.13
Regulation of plasma-cell development. Nat Rev Immunol (2005) 3.98
Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity (2004) 3.75
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J (2010) 3.68
Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol (2002) 3.61
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol (2004) 3.50
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med (2001) 3.36
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
Regulation and functions of Rho-associated kinase. Exp Cell Res (2000) 3.11
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood (2005) 2.79
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol (2010) 2.75
Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem (2002) 2.67
Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol (2003) 2.58
In vivo flow cytometer for real-time detection and quantification of circulating cells. Opt Lett (2004) 2.46
Expansion of human SCID-repopulating cells under hypoxic conditions. J Clin Invest (2003) 2.37
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol (2002) 2.37
Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol (2001) 2.32
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci U S A (2002) 2.26
Chemokines in the systemic organization of immunity. Immunol Rev (2003) 2.25
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol (2004) 2.23
The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med (2004) 2.14
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol (2002) 1.99
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Pathogenesis of myeloma. Annu Rev Pathol (2011) 1.91
Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol (2003) 1.82
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood (2000) 1.81
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Plasma cells: finding new light at the end of B cell development. Nat Immunol (2001) 1.74
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion (2005) 1.71
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant (2007) 1.65
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem (2002) 1.59
Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica (2005) 1.52
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res (2003) 1.51
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther (2002) 1.50
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood (2010) 1.48
Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol (2001) 1.47
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem (2001) 1.45
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia (2011) 1.39
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood (2009) 1.39
Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol (2006) 1.35
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
Signaling to myosin regulatory light chain in sarcomeres. J Biol Chem (2011) 1.33
Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood (2006) 1.31
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer (2003) 1.30
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol (2007) 1.27
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am (2007) 1.26
Expression and function of chemokine receptors in human multiple myeloma. Leukemia (2003) 1.26
The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J (2000) 1.25
Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma (2000) 1.25
Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol (2002) 1.22
Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res (2011) 1.20
Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood (1997) 1.19
Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem (2003) 1.19
Chemokines in multiple myeloma. Exp Hematol (2006) 1.18
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica (2005) 1.14
Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res (1995) 1.10
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood (2010) 2.40
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma (2010) 2.20
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood (2008) 2.10
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood (2004) 1.82
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clin Proc (2010) 1.80
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood (2005) 1.79
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood (2010) 1.79
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood (2011) 1.77
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood (2010) 1.71
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 1.60
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma (2008) 1.54
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood (2014) 1.47
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood (2004) 1.46
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood (2011) 1.46
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood (2009) 1.40
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood (2009) 1.39
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol (2009) 1.38
Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood (2008) 1.36
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc (2010) 1.34
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood (2012) 1.32
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res (2007) 1.32
Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med (2011) 1.31
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res (2007) 1.30
Transplantation for amyloidosis. Curr Opin Oncol (2007) 1.29
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res (2005) 1.25
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood (2008) 1.24
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood (2007) 1.24
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood (2005) 1.23
Plasma cell labeling index. Methods Mol Med (2005) 1.22
Chemokines in multiple myeloma. Exp Hematol (2006) 1.18
Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev (2015) 1.16
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2008) 1.16
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol (2008) 1.15
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol (2011) 1.14
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res (2006) 1.14
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol (2012) 1.14
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc (2008) 1.13
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood (2010) 1.13
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood (2010) 1.11
Defining the role of TORC1/2 in multiple myeloma. Blood (2011) 1.10
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol (2010) 1.10
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc (2012) 1.09
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol (2009) 1.08
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood (2009) 1.07
Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res (2007) 1.07
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood (2012) 1.07
An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther (2003) 1.07
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood (2012) 1.06
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant (2008) 1.03
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer (2014) 1.03